BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27714530)

  • 1. Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
    Thamlikitkul L; Srimuninnimit V; Akewanlop C; Ithimakin S; Techawathanawanna S; Korphaisarn K; Chantharasamee J; Danchaivijitr P; Soparattanapaisarn N
    Support Care Cancer; 2017 Feb; 25(2):459-464. PubMed ID: 27714530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
    Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
    Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
    Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
    Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy.
    Pillai AK; Sharma KK; Gupta YK; Bakhshi S
    Pediatr Blood Cancer; 2011 Feb; 56(2):234-8. PubMed ID: 20842754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
    Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial.
    Panahi Y; Saadat A; Sahebkar A; Hashemian F; Taghikhani M; Abolhasani E
    Integr Cancer Ther; 2012 Sep; 11(3):204-11. PubMed ID: 22313739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
    Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
    Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
    Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.
    Bossi P; Cortinovis D; Fatigoni S; Cossu Rocca M; Fabi A; Seminara P; Ripamonti C; Alfieri S; Granata R; Bergamini C; Agustoni F; Bidoli P; Nolè F; Pessi MA; Macchi F; Michellini L; Montanaro F; Roila F
    Ann Oncol; 2017 Oct; 28(10):2547-2551. PubMed ID: 28666335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.
    Ryan JL; Heckler CE; Roscoe JA; Dakhil SR; Kirshner J; Flynn PJ; Hickok JT; Morrow GR
    Support Care Cancer; 2012 Jul; 20(7):1479-89. PubMed ID: 21818642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
    Wenzell CM; Berger MJ; Blazer MA; Crawford BS; Griffith NL; Wesolowski R; Lustberg MB; Phillips GS; Ramaswamy B; Mrozek E; Flynn JM; Shapiro CL; Layman RM
    Support Care Cancer; 2013 Oct; 21(10):2845-51. PubMed ID: 23748485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
    Rugo HS; Rossi G; Rizzi G; Aapro M
    Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
    Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
    Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
    Feinberg B; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
    Support Care Cancer; 2012 Mar; 20(3):615-23. PubMed ID: 21761096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.